Suchergebnisse - "McEllistrim, C"

PubPharm (4)

1

CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma : Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

enthalten in: Clinical lymphoma, myeloma & leukemia | 2022

von Swan, D. | Henderson, R. | McEllistrim, C. | +15

2

CyBorD-DARA is potent initial induction for MM and enhances ADCP : initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study

enthalten in: Blood advances | 2019

von O'Dwyer, M. | Henderson, R. | Naicker, S. | +17

3

E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271

enthalten in: Leukemia | 2017

von Natoni, A. | Smith, T. | Keane, N. | +14

4

New developments in the treatment of multiple myeloma – clinical utility of daratumumab

in: Biologics: Targets & Therapy | 2017

von McEllistrim C | Krawczyk J | O'Dwyer ME

1
[1]